News coverage about Johnson & Johnson (NYSE:JNJ) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.4716992724787 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- The boycott of Laura Ingraham’s Fox News show barely registered with consumers (with one exception) (finance.yahoo.com)
- Which Big Pharma CEOs Least Deserved Their Big Pay Increases? (finance.yahoo.com)
- Analysts’ Recommendations for Johnson & Johnson in March 2018 (finance.yahoo.com)
- IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm (finance.yahoo.com)
- Malaysia Eyewear Market Analysis & Outlook 2011-2021 – Key Players are Luxottica, Johnson & Johnson and Hoya Corp – ResearchAndMarkets.com (markets.financialcontent.com)
JNJ has been the subject of several research analyst reports. Wells Fargo reaffirmed an “outperform” rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research report on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $144.43.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. equities research analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.
In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.